Are increasing 5-year survival rates evidence of success against cancer?
- PMID: 10865276
- DOI: 10.1001/jama.283.22.2975
Are increasing 5-year survival rates evidence of success against cancer?
Abstract
Context: Increased 5-year survival for cancer patients is generally inferred to mean that cancer treatment has improved and that fewer patients die of cancer. Increased 5-year survival, however, may also reflect changes in diagnosis: finding more people with early-stage cancer, including some who would never have become symptomatic from their cancer.
Objective: To determine the relationship over time between 5-year cancer survival and 2 other measures of cancer burden, mortality and incidence.
Design and setting: Using population-based statistics reported by the National Cancer Institute Surveillance, Epidemiology, and End Results Program, we calculated the change in 5-year survival from 1950 to 1995 for the 20 most common solid tumor types. Using the tumor as the unit of analysis, we correlated changes in 5-year survival with changes in mortality and incidence.
Main outcome measure: The association between changes in 5-year survival and changes in mortality and incidence measured using simple correlation coefficients (Pearson and Spearman).
Results: From 1950 to 1995, there was an increase in 5-year survival for each of the 20 tumor types. The absolute increase in 5-year survival ranged from 3% (pancreatic cancer) to 50% (prostate cancer). During the same period, mortality rates declined for 12 types of cancer and increased for the remaining 8 types. There was little correlation between the change in 5-year survival for a specific tumor and the change in tumor-related mortality (Pearson r=.00; Spearman r=-.07). On the other hand, the change in 5-year survival was positively correlated with the change in the tumor incidence rate (Pearson r=+. 49; Spearman r=+.37).
Conclusion: Although 5-year survival is a valid measure for comparing cancer therapies in a randomized trial, our analysis shows that changes in 5-year survival over time bear little relationship to changes in cancer mortality. Instead, they appear primarily related to changing patterns of diagnosis. JAMA. 2000.
Comment in
-
Do increased 5-year survival rates in prostate cancer indicate better outcomes?JAMA. 2000 Oct 25;284(16):2053-4; author reply 2054-5. doi: 10.1001/jama.284.16.2053-a. JAMA. 2000. PMID: 11042743 No abstract available.
-
Do increased 5-year survival rates in prostate cancer indicate better outcomes?JAMA. 2000 Oct 25;284(16):2054-5. JAMA. 2000. PMID: 11042744 No abstract available.
Similar articles
-
When do changes in cancer survival mean progress? The insight from population incidence and mortality.J Natl Cancer Inst Monogr. 2014 Nov;2014(49):187-97. doi: 10.1093/jncimonographs/lgu014. J Natl Cancer Inst Monogr. 2014. PMID: 25417232 Free PMC article.
-
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035. Epidemiol Prev. 2016. PMID: 26951748
-
Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2018;47(4):203-211. doi: 10.17849/insm-47-04-1-9.1. Epub 2019 Jan 22. J Insur Med. 2018. PMID: 30668210
-
Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program.Oncologist. 2003;8(6):541-52. doi: 10.1634/theoncologist.8-6-541. Oncologist. 2003. PMID: 14657533 Review.
-
Socioeconomic factors and breast carcinoma in multicultural women.Cancer. 2000 Mar 1;88(5 Suppl):1256-64. doi: 10.1002/(sici)1097-0142(20000301)88:5+<1256::aid-cncr13>3.0.co;2-3. Cancer. 2000. PMID: 10705364 Review.
Cited by
-
Deciphering Trends in Cancer Mortality: A Comprehensive Analysis of Brazilian Data From 1979 to 2021 With Emphasis on Breast and Prostate Cancers.World J Oncol. 2024 Jun;15(3):463-471. doi: 10.14740/wjon1831. Epub 2024 Apr 15. World J Oncol. 2024. PMID: 38751694 Free PMC article.
-
Regards sur les séquelles psychosociales des cancers pédiatriques sur le parcours de réintégration des jeunes survivants devenus adultes: étude qualitative exploratoire.Can Oncol Nurs J. 2024 Apr 1;34(2):187-195. doi: 10.5737/23688076342187. eCollection 2024 Spring. Can Oncol Nurs J. 2024. PMID: 38706648 Free PMC article. French.
-
Unveiling perspectives on the psychosocial impacts of childhood cancer survival on young adult survivors' reassimilation journey: A qualitative exploration.Can Oncol Nurs J. 2024 Apr 1;34(2):179-186. doi: 10.5737/23688076342179. eCollection 2024 Spring. Can Oncol Nurs J. 2024. PMID: 38706646 Free PMC article.
-
mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation.Front Oncol. 2024 Jan 25;14:1312634. doi: 10.3389/fonc.2024.1312634. eCollection 2024. Front Oncol. 2024. PMID: 38344201 Free PMC article. Review.
-
Exploring the links of skeletal muscle mitochondrial oxidative capacity, physical functionality, and mental well-being of cancer survivors.Sci Rep. 2024 Feb 1;14(1):2669. doi: 10.1038/s41598-024-52570-x. Sci Rep. 2024. PMID: 38302539 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources

